These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 14975372)

  • 1. Possible molecular mechanisms to account for the efficacy of allopurinol against experimental autoimmune uveitis.
    Namazi MR
    Int Immunopharmacol; 2004 Jan; 4(1):161-2. PubMed ID: 14975372
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-tumor necrosis factor-α agents in noninfectious uveitis.
    Gueudry J; LeHoang P; Bodaghi B
    Dev Ophthalmol; 2012; 51():63-78. PubMed ID: 22517205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of tumor necrosis factor inhibitors in uveitis.
    Rabinovich CE
    Curr Opin Rheumatol; 2007 Sep; 19(5):482-6. PubMed ID: 17762615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cetirizine and allopurinol as novel weapons against cellular autoimmune disorders.
    Namazi MR
    Int Immunopharmacol; 2004 Mar; 4(3):349-53. PubMed ID: 15037212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting T regulatory cells in autoimmune diseases.
    Toubi E
    Isr Med Assoc J; 2008 Jan; 10(1):73-6. PubMed ID: 18300580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allopurinol has immunomodulating activity following topical and systemic application in experimental autoimmune uveitis.
    Grus FH; Augustin AJ; Loeffler K; Dick B; Lutz J; Pfeiffer N
    Eur J Ophthalmol; 2001; 11(3):252-60. PubMed ID: 11681504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralizing TNF-alpha activity modulates T-cell phenotype and function in experimental autoimmune uveoretinitis.
    Dick AD; Duncan L; Hale G; Waldmann H; Isaacs J
    J Autoimmun; 1998 Jun; 11(3):255-64. PubMed ID: 9693974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon-a (IFN-a) application versus tumor necrosis factor-a antagonism for ocular Behçet's disease: focusing more on IFN.
    Kotter I; Deuter C; Stubiger N; Zierhut M
    J Rheumatol; 2005 Aug; 32(8):1633; author reply 1634. PubMed ID: 16078350
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of the efficacy of unilateral, bilateral, and oral cyclosporine in experimental immunogenic uveitis in rabbits.
    Kaswan RL; Kaplan HJ
    Transplant Proc; 1988 Jun; 20(3 Suppl 4):149-57. PubMed ID: 3289202
    [No Abstract]   [Full Text] [Related]  

  • 10. New biologic drugs: anti-interleukin therapy.
    Tappeiner C; Möller B; Hennig M; Heiligenhaus A
    Dev Ophthalmol; 2012; 51():79-89. PubMed ID: 22517206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab in uveitis treatment.
    Rudometkin N; Mandava N; Deane K; Olson JL
    Arch Ophthalmol; 2006 Aug; 124(8):1211; author reply 1211-2. PubMed ID: 16908832
    [No Abstract]   [Full Text] [Related]  

  • 12. Down-regulation of cell adhesion molecules LFA-1 and ICAM-1 after in vitro treatment with the anti-TNF-alpha agent thalidomide.
    Settles B; Stevenson A; Wilson K; Mack C; Ezell T; Davis MF; Taylor LD
    Cell Mol Biol (Noisy-le-grand); 2001 Nov; 47(7):1105-14. PubMed ID: 11838958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of MMP-dependent chemotaxis and amelioration of experimental autoimmune uveitis with a selective metalloproteinase-2 and -9 inhibitor.
    El-Shabrawi Y; Walch A; Hermann J; Egger G; Foster CS
    J Neuroimmunol; 2004 Oct; 155(1-2):13-20. PubMed ID: 15342192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IFN-gamma increases the severity and accelerates the onset of experimental autoimmune uveitis in transgenic rats.
    Egwuagu CE; Sztein J; Mahdi RM; Li W; Chao-Chan C; Smith JA; Charukamnoetkanok P; Chepelinsky AB
    J Immunol; 1999 Jan; 162(1):510-7. PubMed ID: 9886427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dramatic improvement following interleukin 1beta blockade in tumor necrosis factor receptor-1-associated syndrome (TRAPS) resistant to anti-TNF-alpha therapy.
    Sacré K; Brihaye B; Lidove O; Papo T; Pocidalo MA; Cuisset L; Dodé C
    J Rheumatol; 2008 Feb; 35(2):357-8. PubMed ID: 18260167
    [No Abstract]   [Full Text] [Related]  

  • 16. FK 506 treatment of experimental autoimmune uveoretinitis in primates.
    Fujino Y; Chan CC; de Smet MD; Hikita N; Gery I; Mochizuki M; Nussenblatt RB
    Transplant Proc; 1991 Dec; 23(6):3335-8. PubMed ID: 1721454
    [No Abstract]   [Full Text] [Related]  

  • 17. Biologic agents in experimental autoimmune uveitis.
    Giuliari GP; Sadaka A; Hinkle DM
    Int Ophthalmol; 2014 Feb; 34(1):145-56. PubMed ID: 23494482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging small molecule and biological therapeutic approaches for the treatment of autoimmunity.
    Leishman AJ; Sims GP; Sleeman M; Braddock M
    Expert Opin Investig Drugs; 2011 Jan; 20(1):23-39. PubMed ID: 21118058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of activin A on tumor necrosis factor-alpha/intercellular adhesion molecule-1 pathway in endometrial stromal cells.
    Mangioni S; Viganò P; Florio P; Borghi O; Vignali M; Petraglia F; Di Blasio AM
    Eur J Obstet Gynecol Reprod Biol; 2005 Dec; 123(2):218-23. PubMed ID: 15893868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The suppressive effect of triptolide on experimental autoimmune uveoretinitis by down-regulating Th1-type response.
    Wu Y; Wang Y; Zhong C; Li Y; Li X; Sun B
    Int Immunopharmacol; 2003 Oct; 3(10-11):1457-65. PubMed ID: 12946442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.